Vnitr Lek 2016, 62(7-8):635-639

Systolic blood pressure targets

Miroslav Souček
II. interní klinika LF MU a ICRC FN u sv. Anny v Brně

When treating systolic hypertension we do not know the optimum blood pressure which leads to the reduction of cardiovascular events and cardiovascular and total mortality. The results of the ACCORD study, when comparing intensive treatment of systolic blood pressure (SBP) < 120 mm Hg and standard treatment < 140 mm Hg, did not lead to affecting the primary target for patients with diabetes mellitus. The SPRINT study (Systolic Blood Pressure Intervention Trial) has shown that more intensive treatment of hypertension (aimed at readings lower than the generally recommended target readings) significantly reduces incidence of cardiovascular diseases and lowers the risk of death. On the other hand, a statistically significant incidence of side effects (hypotension, syncope, renal impairment or failure) has been identified. The first results were presented at the American Heart Association Congress on 9 November 2015.

Keywords: target values; hypotension; cardiovascular events; systolic blood pressure

Received: July 15, 2016; Accepted: August 1, 2016; Published: July 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Souček M. Systolic blood pressure targets. Vnitr Lek. 2016;62(7-8):635-639.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Franklin SS, Jacobs MJ, Wong ND et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001; 37(3): 869-874. Go to original source... Go to PubMed...
    2. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003; 289(19): 2560-2572. Go to original source... Go to PubMed...
    3. Hsu CY, McCulloch CE, Darbinian J et al. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005; 165(8): 923-928. Go to original source... Go to PubMed...
    4. Sundström J, Arima H, Jackson R et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015; 162(3): 184-191. Go to original source... Go to PubMed...
    5. Neal B, MacMahon S, Chapman N et al. Effects of ACE inhibitors, calcium antagonists, and other blood - pressure - lowering drugs: results of prospectively designed overview of radomised trials. Lancet 2000; 356(9246): 1955-1964. Go to original source... Go to PubMed...
    6. Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: systematic review and meta-analysis. JAMA 1997; 277(9): 739-745. Go to original source...
    7. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903-1913. Go to original source... Go to PubMed...
    8. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358(18): 1887-1898. Go to original source... Go to PubMed...
    9. Verdecchia P, Staessen JA, Angeli F et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio.Sis): a open-label randomised trial. Lancet 2009; 374(9689): 525-533. Erratum in Lancet 2009; 374(9693): 880. Go to original source... Go to PubMed...
    10. Cushman WC, Evans GW, Byington RP et al. [ACCORD Study Group]. Effect of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1575-1585. Go to original source... Go to PubMed...
    11. Benavente OR, Coffey CS, Conwit R et al. [SPS3 Study Group]. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randosed trial. Lancet 2013; 382(9891): 507-515. Erratum in Lancet 2013; 382(9891): 506. Go to original source... Go to PubMed...
    12. Wright JT, Williamson PK, Snyder JK et al. [SPRINT Research Group]. A Randomised Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373(22): 2103-2116. Go to original source... Go to PubMed...
    13. Perkovic V, Rodgers A. Redefining Blood-Pressure Targets - SPRINT starts the Marathon. N Engl J Med 2015; 373(22): 2175-2178. Go to original source... Go to PubMed...
    14. Drazen JM, Morrissey S, Campion EW et al. A SPRINT to the Finish. N Engl J Med 2015; 373(22): 2174-2175. Go to original source... Go to PubMed...
    15. Cífková R. Změní výsledky studie SPRINT dosavadní doporučení pro léčbu hypertenze? Hypertenze - kardiovaskulární prevence 2016; 5(1): 15-17.
    16. Souček M. Studie SPRINT. Kam až snižovat systolický krevní tlak. Hypertenze - kardiovaskulární prevence 2016; 5(1)1: 11-14.
    17. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on a outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens 2014; 32(12): 2285-2295. Go to original source... Go to PubMed...
    18. Filipovský J, Widimský J, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Hypertenze - kardiovaskulární prevence 2013; 1(3): 1-16.
    19. Souček M, Widimský J, Lánská V. Control of hypertension in patients with hypertension, diabetes a impaired fasting glucose by Czech primary care physicians. Kidney Blood Press Res 2006; 29(6): 366-372. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.